Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

21 Jun 2026, 15:43 UTC · 2h ago

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Ultragenyx expects pivotal Phase 3 Aspire results for GTX-102 in Angelman syndrome. — Pivotal Phase 3 results for a major unmet need are high-volatility events that can either validate the platform or cause significant price drops.
+0.80
2
The FDA will review DTX401 and UX111 with PDUFA dates scheduled for H2 2026. — Regulatory approval dates provide concrete timelines for potential new revenue streams and market expansion.
+0.60
3
The company reaffirmed its 2026 revenue guidance of $730–$760 million despite a recent Phase 3 failure. — Maintaining guidance after a clinical setback signals commercial resilience and operational stability to investors.
+0.40
4

6 related stories

The Motley Fool
6h ago
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
- biotech
- fda approval
- healthcare
Read

Ultragenyx: The Setrusuma… — RARE +0.40 | NewsImpactScreener

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

What matters in this story

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

What matters in this story

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

3 Biotech Firms With Major Potential Catalysts in the Coming Months

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

AbbVie would gain an experimental eczema drug by buying biotech: report

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

XBI: A "Hidden" ETF Up +70% In 1 Year.

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

What matters in this story

Next reads from the same story arc

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity

What matters in this story

Next reads from the same story arc

Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

3 Biotech Firms With Major Potential Catalysts in the Coming Months

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

AbbVie would gain an experimental eczema drug by buying biotech: report

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

XBI: A "Hidden" ETF Up +70% In 1 Year.